Mijntje Matheeuwsen
University of Amsterdam
Intensive care medicineCochrane LibraryMaintenance therapyBiosimilarMedicine
What is this?
Publications 3
#1Toer W. Stevens (UvA: University of Amsterdam)H-Index: 2
#2Mijntje Matheeuwsen (UvA: University of Amsterdam)H-Index: 1
Last. Geert D'Haens (UvA: University of Amsterdam)H-Index: 43
view all 7 authors...
Background: Inflammatory bowel disease (IBD) is characterised by substantial heterogeneity in treatment response. With an expanding number of therapeutic agents, identifying optimal treatment at the patient level remains a major challenge. Aim: To systematically review the available literature on predictive biomarkers of therapeutic response in IBD. Methods: An electronic literature search was performed on 30 January 2018 using MEDLINE, EMBASE and the Cochrane Library. Retrospective, prospective...
5 CitationsSource
#1Anne S. StrikH-Index: 5
#2Erwin Dreesen (Katholieke Universiteit Leuven)H-Index: 8
Last. Geert R. D'HaensH-Index: 61
view all 7 authors...
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The objective of the review is to evaluate whether switching IBD patients from the originator to the biosimilar IFX is safe and effective in patients with quiescent IBD receiving maintenance therapy.